Last reviewed · How we verify
Vasodilator
Vasodilator is a Small molecule drug developed by Indiana University. It is currently in Phase 2 development. Also known as: stress vasodilator.
Vasodilator is a small molecule that acts as an antagonist to the adrenergic receptor alpha, which is involved in the regulation of blood vessel constriction. It is classified as an antagonist and is used to treat various conditions, including fibromyalgia, central neuropathic pain, cardiovascular disease, and hyperlipidemia.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Vasodilator |
|---|---|
| Also known as | stress vasodilator |
| Sponsor | Indiana University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- SMILE Trial - Imaging Sub-Study
- The Multicenter Stress Cardiac Magnetic Resonance Quantitative Perfusion Imaging in the United States Study (NA)
- Effect of Topically-applied Milrinone or Nitroglycerin on Internal Mammary Artery Free Flow (PHASE3)
- Subcutaneous Nitroglycerin to Facilitate Trans-radial Access. (PHASE4)
- Effect of iNO in Patients With Submassive and Massive PE (PHASE2)
- Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy (PHASE1, PHASE2)
- Field Study on Intravenous Iloprost for Treatment of Severe Frostbite at High Altitude
- N2O for Acute Suicidality and Depression in the ED (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vasodilator CI brief — competitive landscape report
- Vasodilator updates RSS · CI watch RSS
- Indiana University portfolio CI
Frequently asked questions about Vasodilator
What is Vasodilator?
Who makes Vasodilator?
Is Vasodilator also known as anything else?
What development phase is Vasodilator in?
Related
- Manufacturer: Indiana University — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: stress vasodilator
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing